...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Private placement one million plus units for US$2, half wt exercisable at US3, good for 3 years

interesting that the exercise price period would be so far out. Is that a realistic guess of the timing of a sale or a big fat stinky red herring? Economic conditions, funding requirements and a little shareholder fiscal desperation make this a heck of a good time for a BP to float a low ball takeover offer for both companies.

Share
New Message
Please login to post a reply